For hospitalized patients with Middle East Respiratory Syndrome, treatment with IFN-β and lopinavir-ritonavir led to significantly lower mortality than placebo (of note, there was no IFN-β alone comparison group) [58]. Here, IFNB1 is linked to Middle East respiratory syndrome.